Cbdmd Inc Financials

YCBD

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE September

This page shows Cbdmd Inc (YCBD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 36/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Cbdmd Inc has an operating margin of -11.3%, meaning the company retains $-11 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -17.0% the prior year.

Growth

Cbdmd Inc's revenue declined 1.5% year-over-year, from $19.5M to $19.2M. This contraction results in a growth score of 24/100.

Leverage

Cbdmd Inc carries a low D/E ratio of 0.44, meaning only $0.44 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Cbdmd Inc's current ratio of 2.05 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Cbdmd Inc generated -$1.5M in operating cash flow, capex of $184K consumed most of it, leaving -$1.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

5/9

Cbdmd Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.71x

For every $1 of reported earnings, Cbdmd Inc generates $0.71 in operating cash flow (-$1.5M OCF vs -$2.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-63.0x

Cbdmd Inc earns $-63.0 in operating income for every $1 of interest expense (-$2.2M vs $34K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$19.2M

YoY-1.5%

5Y CAGR-14.5%

Cbdmd Inc generated $19.2M in revenue in fiscal year 2025. This represents a decrease of 1.5% from the prior year.

EBITDA

-$1.0M

YoY+52.1%

Cbdmd Inc's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.1% from the prior year.

Free Cash Flow

-$1.6M

YoY-201.5%

Cbdmd Inc generated -$1.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 201.5% from the prior year.

Net Income

-$2.0M

YoY+44.8%

Cbdmd Inc reported -$2.0M in net income in fiscal year 2025. This represents an increase of 44.8% from the prior year.

EPS (Diluted)

$-1.09

Cbdmd Inc earned $-1.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 92.4% from the prior year.

Cash & Debt

$2.3M

YoY-7.8%

5Y CAGR-31.3%

Cbdmd Inc held $2.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Cbdmd Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 1711.0% from the prior year.

Gross Margin

62.4%

YoY+0.8pp

5Y CAGR-0.6pp

Cbdmd Inc's gross margin was 62.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the prior year.

Operating Margin

-11.3%

YoY+5.8pp

5Y CAGR+30.7pp

Cbdmd Inc's operating margin was -11.3% in fiscal year 2025, reflecting core business profitability. This is up 5.8 percentage points from the prior year.

Net Margin

-10.6%

YoY+8.4pp

5Y CAGR-40.7pp

Cbdmd Inc's net profit margin was -10.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8.4 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$184K

YoY-3.1%

5Y CAGR-32.6%

Cbdmd Inc invested $184K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 3.1% from the prior year.

YCBD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$19.2M-1.5%	$19.5M-19.3%	$24.2M-31.8%	$35.4M-20.4%	$44.5M+6.2%	$41.9M
Cost of Revenue	$7.2M-3.5%	$7.5M-18.4%	$9.2M-29.8%	$13.1M-9.9%	$14.5M-6.6%	$15.5M
Gross Profit	$12.0M-0.2%	$12.0M-19.9%	$15.0M-32.9%	$22.3M-25.5%	$30.0M+13.7%	$26.4M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$2.2M+34.8%	-$3.3M+85.3%	-$22.5M+71.3%	-$78.3M-299.0%	-$19.6M-11.6%	-$17.6M
Interest Expense	$34K+216.3%	-$30K-146.3%	$64K+292.1%	$16K+156.2%	-$29K-172.5%	$40K
Income Tax	$0	$0	$0	$0+100.0%	-$895K-166.5%	$1.3M
Net Income	-$2.0M+44.8%	-$3.7M+83.9%	-$22.9M+67.3%	-$70.1M-199.6%	-$23.4M-285.6%	$12.6M
EPS (Diluted)	$-1.09	$-14.29	$-13.32+76.1%	$-55.80	$-0.47-267.9%	$0.28

Metric	Q3'25	Q2'25	Q1'24	Q3'24	Q2'24	Q1'23	Q3'23	Q2'23
Revenue	$4.6M-3.0%	$4.7M-7.1%	$5.1M-1.2%	$5.2M+18.2%	$4.4M-18.6%	$5.4M-12.2%	$6.1M-1.9%	$6.2M
Cost of Revenue	$1.8M-0.8%	$1.8M+4.5%	$1.7M-3.2%	$1.8M-1.4%	$1.8M-1.2%	$1.8M-20.1%	$2.3M+2.2%	$2.2M
Gross Profit	$2.8M-4.3%	$3.0M-13.0%	$3.4M-0.1%	$3.4M+31.9%	$2.6M-27.5%	$3.6M-7.5%	$3.8M-4.2%	$4.0M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$905K-86.2%	-$486K-463.1%	-$86K+77.4%	-$382K+75.4%	-$1.6M-45.5%	-$1.1M+41.6%	-$1.8M-30.2%	-$1.4M
Interest Expense	$9K+23.2%	$8K-33.0%	$11K+189.5%	-$13K+30.8%	-$18K-4301.7%	-$418+66.5%	-$1K+36.0%	-$2K
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	-$895K-86.2%	-$481K-3284.9%	$15K+109.9%	-$153K+94.9%	-$3.0M-202.1%	-$997K+93.7%	-$15.9M-1087.5%	-$1.3M
EPS (Diluted)	N/A	N/A	N/A	$-0.15	$-1.35	N/A	$-1.16+33.3%	$-1.74

YCBD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.4M-1.5%	$10.6M-34.7%	$16.2M-60.3%	$40.8M-67.3%	$124.9M+12.7%	$110.8M
Current Assets	$6.6M+2.5%	$6.4M-20.8%	$8.1M-49.6%	$16.0M-56.1%	$36.5M+53.9%	$23.7M
Cash & Equivalents	$2.3M-7.8%	$2.5M+36.4%	$1.8M-73.2%	$6.7M-74.6%	$26.4M+78.2%	$14.8M
Inventory	$2.9M+16.7%	$2.5M-40.4%	$4.2M-11.2%	$4.8M-14.5%	$5.6M+13.9%	$4.9M
Accounts Receivable	$786K+26.5%	$622K-48.9%	$1.2M+344.7%	$273K	N/A	N/A
Goodwill	N/A	N/A	$0	$0-100.0%	$56.7M+3.7%	$54.7M
Total Liabilities	$3.2M-62.9%	$8.6M+20.3%	$7.2M-23.5%	$9.4M-56.9%	$21.7M-31.3%	$31.7M
Current Liabilities	$3.2M-62.9%	$8.6M+84.5%	$4.7M-11.6%	$5.3M-23.6%	$6.9M-10.0%	$7.7M
Long-Term Debt	N/A	N/A	$9-100.0%	$125K+15.1%	$109K-58.8%	$264K
Total Equity	$7.2M+268.0%	$2.0M-78.3%	$9.0M-71.3%	$31.4M-69.5%	$103.1M+30.3%	$79.2M
Retained Earnings	-$179.4M+1.4%	-$182.1M-4.4%	-$174.4M-18.3%	-$147.4M-101.0%	-$73.3M-54.8%	-$47.4M

Metric	Q3'25	Q2'25	Q1'24	Q3'24	Q2'24	Q1'23	Q3'23	Q2'23
Total Assets	$10.4M-4.7%	$10.9M-5.2%	$11.5M+9.1%	$10.6M-27.3%	$14.6M-3.6%	$15.1M-6.8%	$16.2M-51.9%	$33.7M
Current Assets	$6.6M+5.8%	$6.2M-2.6%	$6.4M-0.4%	$6.4M-13.8%	$7.4M+0.6%	$7.4M-8.7%	$8.1M-20.5%	$10.1M
Cash & Equivalents	$2.3M+28.1%	$1.8M-10.4%	$2.0M-19.7%	$2.5M+16.5%	$2.1M+39.9%	$1.5M-16.3%	$1.8M+4.6%	$1.7M
Inventory	$2.9M+2.2%	$2.9M+16.6%	$2.5M-2.0%	$2.5M-26.9%	$3.5M-7.8%	$3.7M-11.6%	$4.2M-6.5%	$4.5M
Accounts Receivable	$786K+13.2%	$695K+10.1%	$631K+1.5%	$622K-28.4%	$868K+50.5%	$577K-52.6%	$1.2M+259.3%	$339K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Total Liabilities	$3.2M-68.9%	$10.3M+5.2%	$9.8M+13.3%	$8.6M-24.8%	$11.5M+42.3%	$8.1M+12.5%	$7.2M-9.3%	$7.9M
Current Liabilities	$3.2M-67.6%	$9.9M+7.7%	$9.2M+6.4%	$8.6M+24.2%	$6.9M+16.2%	$6.0M+27.9%	$4.7M-0.2%	$4.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$9	$0
Total Equity	$7.2M+985.3%	$666K-62.6%	$1.8M-9.3%	$2.0M-36.4%	$3.1M-56.1%	$7.0M-22.1%	$9.0M-65.0%	$25.8M
Retained Earnings	-$179.4M+2.8%	-$184.5M-0.8%	-$183.1M-0.5%	-$182.1M-0.9%	-$180.4M-2.3%	-$176.4M-1.1%	-$174.4M-12.7%	-$154.7M

YCBD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.5M-311.7%	-$353K+91.8%	-$4.3M+71.3%	-$15.0M-6.2%	-$14.1M-32.2%	-$10.7M
Capital Expenditures	$184K-3.1%	$190K-36.1%	$298K-56.8%	$689K+101.4%	$342K-74.1%	$1.3M
Free Cash Flow	-$1.6M-201.5%	-$543K+88.2%	-$4.6M+70.6%	-$15.7M-8.5%	-$14.4M-20.5%	-$12.0M
Investing Cash Flow	-$184K+36.5%	-$290K-141.3%	$702K+202.0%	-$689K+73.0%	-$2.6M-62.5%	-$1.6M
Financing Cash Flow	$1.4M+11.4%	$1.3M+198.1%	-$1.3M+67.2%	-$4.0M-114.3%	$28.2M+26.2%	$22.4M
Dividends Paid	N/A	N/A	N/A	N/A	$2.6M+596.4%	$367K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'24	Q3'24	Q2'24	Q1'23	Q3'23	Q2'23
Operating Cash Flow	-$241K	N/A	N/A	$167K+123.8%	-$704K-565.0%	-$106K+59.8%	-$264K+84.8%	-$1.7M
Capital Expenditures	$3K-81.9%	$16K-90.6%	$164K+1543.9%	$10K+316.5%	-$5K-102.5%	$185K+53.6%	$120K+217.4%	-$102K
Free Cash Flow	-$244K	N/A	N/A	$157K+122.2%	-$709K-143.9%	-$291K+24.3%	-$384K+79.1%	-$1.8M
Investing Cash Flow	-$3K+81.9%	-$16K+90.6%	-$164K-49.4%	-$110K-2481.0%	$5K+102.5%	-$185K-53.6%	-$120K-110.9%	$1.1M
Financing Cash Flow	$1.4M	$0	$0-100.0%	$1-100.0%	$1.3M+52079.2%	-$3K+99.6%	-$665K+33.7%	-$1.0M
Dividends Paid	N/A	$1.0M-0.6%	$1.0M	N/A	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

YCBD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	62.4%+0.8pp	61.6%-0.4pp	62.0%-1.1pp	63.1%-4.3pp	67.4%+4.4pp	63.0%
Operating Margin	-11.3%+5.8pp	-17.0%+76.1pp	-93.1%+128.0pp	-221.1%-177.0pp	-44.1%-2.1pp	-42.0%
Net Margin	-10.6%+8.4pp	-19.0%+76.0pp	-95.0%+103.0pp	-198.0%-145.4pp	-52.6%-82.7pp	30.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	15.9%
Return on Assets	-19.6%+15.4pp	-35.0%+106.7pp	-141.6%+30.2pp	-171.8%-153.1pp	-18.7%-30.1pp	11.4%
Current Ratio	2.05+1.3	0.74-1.0	1.73-1.3	3.03-2.2	5.28+2.2	3.08
Debt-to-Equity	0.44-3.9	4.39+4.4	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	-8.5%-5.7pp	-2.8%+16.3pp	-19.0%+25.2pp	-44.2%-11.8pp	-32.5%-3.8pp	-28.6%

Metric	Q3'25	Q2'25	Q1'24	Q3'24	Q2'24	Q1'23	Q3'23	Q2'23
Gross Margin	61.5%-0.9pp	62.3%-4.2pp	66.5%+0.7pp	65.8%+6.8pp	59.0%-7.2pp	66.2%+3.3pp	62.8%-1.5pp	64.3%
Operating Margin	-19.6%-9.4pp	-10.2%-8.5pp	-1.7%+5.7pp	-7.4%+28.1pp	-35.4%-15.6pp	-19.8%+10.0pp	-29.8%-7.3pp	-22.4%
Net Margin	-19.4%-9.3pp	-10.1%-10.4pp	0.3%-8.6pp	8.9%+77.7pp	-68.8%-50.2pp	-18.5%+10.4pp	-28.9%-7.5pp	-21.4%
Return on Equity	N/A	N/A	0.9%-14.3pp	15.2%	N/A	N/A	N/A	N/A
Return on Assets	-9.0%-4.7pp	-4.4%-4.5pp	0.1%+1.6pp	-1.4%+19.3pp	-20.7%-14.1pp	-6.6%+91.4pp	-98.0%-94.0pp	-4.0%
Current Ratio	2.05+1.4	0.63-0.1	0.69-0.0	0.74-0.3	1.07-0.2	1.23-0.5	1.73-0.4	2.17
Debt-to-Equity	0.44-15.0	15.43+9.9	5.48+1.1	4.39+0.7	3.71+3.7	0.000.0	0.000.0	0.00
FCF Margin	-15.3%	N/A	N/A	5.6%+21.8pp	-16.2%-10.8pp	-5.4%+0.2pp	-5.6%+23.8pp	-29.4%

Similar Companies

Sunshine Biopharma Inc SBFM

$5.7M

China Pharma CPHI

$3.2M

Sonoma Pharmaceu SNOA

$4.8M

Biofrontera Inc BFRI

$9.1M

Evoke Pharma Inc EVOK

$18.9M

Frequently Asked Questions

What is Cbdmd Inc's annual revenue?

Cbdmd Inc (YCBD) reported $19.2M in total revenue for fiscal year 2025. This represents a -1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cbdmd Inc's revenue growing?

Cbdmd Inc (YCBD) revenue declined by 1.5% year-over-year, from $19.5M to $19.2M in fiscal year 2025.

Is Cbdmd Inc profitable?

No, Cbdmd Inc (YCBD) reported a net income of -$2.0M in fiscal year 2025, with a net profit margin of -10.6%.

What is Cbdmd Inc's earnings per share (EPS)?

Cbdmd Inc (YCBD) reported diluted earnings per share of $-1.09 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Cbdmd Inc's EBITDA?

Cbdmd Inc (YCBD) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cbdmd Inc's gross margin?

Cbdmd Inc (YCBD) had a gross margin of 62.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cbdmd Inc's operating margin?

Cbdmd Inc (YCBD) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cbdmd Inc's net profit margin?

Cbdmd Inc (YCBD) had a net profit margin of -10.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cbdmd Inc's free cash flow?

Cbdmd Inc (YCBD) generated -$1.6M in free cash flow during fiscal year 2025. This represents a -201.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cbdmd Inc's operating cash flow?

Cbdmd Inc (YCBD) generated -$1.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cbdmd Inc's total assets?

Cbdmd Inc (YCBD) had $10.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cbdmd Inc's capital expenditures?

Cbdmd Inc (YCBD) invested $184K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Cbdmd Inc have outstanding?

Cbdmd Inc (YCBD) had 9M shares outstanding as of fiscal year 2025.

What is Cbdmd Inc's current ratio?

Cbdmd Inc (YCBD) had a current ratio of 2.05 as of fiscal year 2025, which is generally considered healthy.

What is Cbdmd Inc's debt-to-equity ratio?

Cbdmd Inc (YCBD) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cbdmd Inc's return on assets (ROA)?

Cbdmd Inc (YCBD) had a return on assets of -19.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cbdmd Inc's cash runway?

Based on fiscal year 2025 data, Cbdmd Inc (YCBD) had $2.3M in cash against an annual operating cash burn of $1.5M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cbdmd Inc's Piotroski F-Score?

Cbdmd Inc (YCBD) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cbdmd Inc's earnings high quality?

Cbdmd Inc (YCBD) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cbdmd Inc cover its interest payments?

Cbdmd Inc (YCBD) has an interest coverage ratio of -63.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Cbdmd Inc?

Cbdmd Inc (YCBD) scores 36 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.